SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Teladoc Health, Inc. – ‘S-4/A’ on 9/11/20 – ‘EX-8.1’

On:  Friday, 9/11/20, at 4:58pm ET   ·   Accession #:  1140361-20-20266   ·   File #:  333-248568

Previous ‘S-4’:  ‘S-4’ on 9/3/20   ·   Latest ‘S-4’:  This Filing   ·   29 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/11/20  Teladoc Health, Inc.              S-4/A                  8:10M                                    Edgarfilings Ltd.

Pre-Effective Amendment to Registration Statement – Securities for a Merger   —   Form S-4   —   SA’33
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration Statement   HTML   4.42M 
                - Securities for a Merger                                        
 2: EX-8.1      Opinion of Counsel re: Tax Matters                  HTML     16K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      6K 
 4: EX-23.2     Consent of Expert or Counsel                        HTML      6K 
 5: EX-99.1     Miscellaneous Exhibit                               HTML      6K 
 6: EX-99.2     Miscellaneous Exhibit                               HTML      6K 
 7: EX-99.3     Miscellaneous Exhibit                               HTML      8K 
 8: EX-99.4     Miscellaneous Exhibit                               HTML      8K 


‘EX-8.1’   —   Opinion of Counsel re: Tax Matters


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

Exhibit 8.1


 
525 UNIVERSITY AVENUE
________

TEL: (650) 470-4500
FAX: (650) 470-4570



                                         September 11, 2020



FIRM/AFFILIATE OFFICES
-----------
BOSTON
CHICAGO
HOUSTON
LOS ANGELES
NEW YORK
WASHINGTON, D.C.
WILMINGTON
-----------
BEIJING
BRUSSELS
FRANKFURT
HONG KONG
LONDON
MOSCOW
MUNICH
PARIS
SÃO PAULO
SEOUL
SHANGHAI
SINGAPORE
TOKYO
TORONTO

Livongo Health, Inc.
50 West Evelyn Avenue, Suite 150
Mountain View, California  94041

Re:          United States Federal Income Tax Considerations

Ladies and Gentlemen:

We have acted as counsel to Livongo Health, Inc., a Delaware corporation (“Lafite”), in connection with the Agreement and Plan of Merger, dated as of August 5, 2020 (the “Merger Agreement”), by and among (i) Lafite, (ii) Teladoc Health, Inc., a Delaware corporation (“Tempranillo”), and (iii) Tempranillo Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of Tempranillo.  This opinion is being delivered in connection with the Registration Statement (File No. 333-248568) on Form S-4 originally filed on September 3, 2020 with the Securities and Exchange Commission, as amended and supplemented through the date hereof (the “Registration Statement”).  Capitalized terms used herein but not defined shall have the meanings set forth in the Merger Agreement.

In rendering the opinion set forth below, we have examined and relied upon, without independent investigation or verification, the accuracy and completeness of the facts, information, representations, covenants and agreements contained in originals or copies, certified or otherwise identified to our satisfaction, of (i) the Merger Agreement, (ii) the Registration Statement, and (iii) such other documents as we have deemed necessary or appropriate as a basis for the opinion set forth below.  We have assumed that the transactions contemplated by the foregoing documents have been or will be consummated in accordance with the operative documents and that such documents accurately reflect the material facts of such transactions.  In addition, we have relied upon the accuracy and completeness of certain statements, representations, covenants and agreements made by Lafite and Tempranillo, including the accuracy and completeness of all representations and covenants set forth in letters dated as of the date hereof from an officer of each of Lafite and Tempranillo (the “Representation Letters”), and we have assumed that the Representation Letters will be re-executed in substantially the same form by appropriate officers and that we will render our opinion pursuant to Section 9.03(d) of the Merger Agreement, each on the Closing Date.  For purposes of rendering our opinion, we have assumed that such statements, representations, covenants and agreements are, and will continue to be, true and correct without regard to any qualification as to knowledge or belief.  Our opinion assumes and is expressly conditioned on, among other things, the initial and continuing accuracy and completeness of the facts, information, representations, covenants and agreements set forth in the documents referred to above (including, without limitation, the Merger Agreement) and the statements, representations, covenants and agreements made by Lafite and Tempranillo, including those set forth in the Representation Letters.

For purposes of our opinion, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, conformed, photostatic or electronic copies, and the authenticity of the originals of such latter documents.  We have assumed that such documents, certificates, and records are duly authorized, valid, and enforceable.  In making our examination of documents, we have assumed that the parties thereto had the power, corporate or otherwise, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or otherwise, and the execution and delivery by such parties of such documents and the validity and binding effect thereof on such parties.

Our opinion is based on the Internal Revenue Code of 1986, as amended (the “Code”), Treasury regulations promulgated thereunder, judicial decisions, published positions of the Internal Revenue Service (the “Service”), and such other authorities as we have considered relevant, all as in effect on the date of this opinion and all of which are subject to change or differing interpretations, possibly with retroactive effect.  A change in the authorities upon which our opinion is based could affect the conclusions expressed herein.  Moreover, there can be no assurance that our opinion will be accepted by the Service or, if challenged, by a court.

Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth herein and in the Registration Statement under the heading “U.S. Federal Income Tax Considerations”, we are of the opinion that, for United States federal income tax purposes, the Merger will qualify as a “reorganization” within the meaning of Section 368(a) of the Code, with the U.S. federal income tax consequences to U.S. holders (as defined in the Registration Statement) of Lafite stock as described under “—U.S. Holders—Tax Consequences of the Merger” in the Registration Statement and the U.S. federal income tax consequences to non-U.S. holders (as defined in the Registration Statement) of Lafite stock as described under “—Non-U.S. Holders—Tax Consequences of the Merger” in the Registration Statement.

Except as expressly set forth above, we express no other opinion.  This opinion has been prepared in connection with the Registration Statement and may not be relied upon for any other purpose without our prior written consent.

This opinion is being delivered prior to the consummation of the Merger and therefore is prospective and dependent on future events.  This opinion is expressed as of the date hereof, and we are under no obligation to supplement or revise our opinion to reflect any legal developments, any factual matters arising subsequent to the date hereof, or the impact of any information, document, certificate, record, statement, representation, covenant, or assumption relied upon herein that becomes incorrect or untrue.

In accordance with the requirements of Item 601(b)(23) of Regulation S-K under the Securities Act, we hereby consent to the filing of this opinion as an exhibit to the Registration Statement and the use of our name under the heading “U.S. Federal Income Tax Considerations” in the Registration Statement.  In giving this consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the SEC thereunder.

 
Very truly yours,
   
  /s/ Skadden, Arps, Slate, Meagher & Flom LLP
 


2

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-4/A’ Filing    Date    Other Filings
Filed on:9/11/204,  CORRESP
9/3/204,  425,  8-K,  S-4
8/5/204,  425,  8-K
 List all Filings 


29 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/03/20  Teladoc Health, Inc.              S-4                    8:6.1M                                   Broadridge Fin’l So… Inc
 9/03/20  Teladoc Health, Inc.              8-K:8,9     9/03/20   11:10M                                    Toppan Merrill/FA
 8/10/20  Livongo Health, Inc.              10-Q        6/30/20  102:13M
 8/06/20  Livongo Health, Inc.              8-K:1,9     8/05/20    3:837K                                   Donnelley … Solutions/FA
 8/06/20  Teladoc Health, Inc.              8-K:1,9     8/05/20   12:1.3M                                   Toppan Merrill/FA
 8/05/20  Livongo Health, Inc.              8-K:8,9     8/05/20    2:81K                                    Donnelley … Solutions/FA
 8/05/20  Teladoc Health, Inc.              8-K:8,9     8/05/20   11:278K                                   Toppan Merrill/FA
 7/29/20  Teladoc Health, Inc.              10-Q        6/30/20   75:8.3M                                   Toppan Merrill Bridge/FA
 7/02/20  Teladoc Health, Inc.              8-K:2,3,7,9 7/01/20   11:222K                                   Toppan Merrill/FA
 6/12/20  Teladoc Health, Inc.              8-K:5       6/08/20   10:190K                                   Toppan Merrill/FA
 6/04/20  Livongo Health, Inc.              8-K:1,2,3,8 6/01/20    8:1.1M                                   Donnelley … Solutions/FA
 6/01/20  Teladoc Health, Inc.              8-K:5       5/28/20   10:201K                                   Toppan Merrill/FA
 5/22/20  Livongo Health, Inc.              8-K:5       5/19/20    1:35K
 5/19/20  Teladoc Health, Inc.              8-K:1,2,3,8 5/19/20   11:1.1M                                   Toppan Merrill/FA
 5/15/20  Teladoc Health, Inc.              8-K:1,8,9   5/13/20   13:315K                                   Toppan Merrill/FA
 5/07/20  Livongo Health, Inc.              10-Q        3/31/20   94:9.5M                                   Workiva Inc Wde… FA01/FA
 5/07/20  Teladoc Health, Inc.              8-K:5,9     5/01/20   11:264K                                   Toppan Merrill/FA
 4/29/20  Teladoc Health, Inc.              10-Q        3/31/20   73:6.6M                                   Toppan Merrill Bridge/FA
 4/14/20  Teladoc Health, Inc.              DEF 14A     5/28/20    1:4.2M                                   Toppan Merrill/FA
 4/06/20  Livongo Health, Inc.              DEF 14A     5/19/20    1:1.3M                                   Donnelley … Solutions/FA
 3/27/20  Livongo Health, Inc.              8-K:5,9     3/23/20    2:33K
 3/24/20  Livongo Health, Inc.              10-K       12/31/19  108:16M                                    Workiva Inc Wde… FA01/FA
 2/27/20  Teladoc Health, Inc.              8-K:5,7,8,9 2/21/20   11:205K                                   Toppan Merrill/FA
 2/26/20  Teladoc Health, Inc.              10-K       12/31/19  115:23M                                    Toppan Merrill Bridge/FA
 2/25/19  Teladoc Health, Inc.              8-K:5,9     2/22/19    2:297K                                   Toppan Merrill/FA
 8/10/18  Teladoc Health, Inc.              8-K:5,9     8/10/18    3:277K                                   Toppan Merrill/FA
 7/23/18  Teladoc Health, Inc.              S-3ASR      7/23/18    7:930K                                   Toppan Merrill-FA
 6/01/18  Teladoc Health, Inc.              8-K:5,9     5/31/18    2:76K                                    Toppan Merrill/FA
 5/31/17  Teladoc Health, Inc.              8-K:5,9     5/25/17    4:496K                                   Toppan Merrill/FA
Top
Filing Submission 0001140361-20-020266   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 1, 11:56:20.3am ET